Abstract
Paragangliomas are rare neuroendocrine tumours arising from neural crest-derived tissue. In the head and neck region typical locations are the carotid bifurcation, vagal nerve or jugulotympanic region. Paragangliomas are normally benign, and malignant transformation is rare. During the past decade the understanding of the genetic and molecular aetiology has had an important clinical impact on the management of PGs. This is a retrospective review of all histologically verified paragangliomas diagnosed and managed at an academic tertiary care referral centre between 1990 and 2010. Data on age, sex, symptoms, tumour location, management and follow-up were recorded. There were 64 patients with 74 tumours. Thirty-six per cent of the tumours were located in the carotid body region, 48 % in the jugulotympanic region and 15 % in the vagal nerve. One tumour was located in the dorsal neck. Most (95 %) of the patients were treated primarily with surgery and with curative intent. Definitive radiation therapy was primarily given to two patients. Recurrent or residual tumours were treated with surgery in three patients and with radiation therapy in nine patients. The typical long-term post-operative sequel was vocal cord paralysis. Local recurrence was found in 6 % of patients. Symptoms and findings related to paragangliomas are variable and management should be individualized. Surgery remains the primary choice of the current treatment options, but often is challenging and warrants a multidisciplinary approach. We present an algorithm on the management of head and neck paragangliomas based on current knowledge.
Similar content being viewed by others
References
Martin TP, Irving RM, Maher ER (2007) The genetics of paragangliomas: a review. Clin Otolaryngol 32(1):7–11. doi:10.1111/j.1365-2273.2007.01378.x
Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366(9486):665–675 pii:S0140-6736(05)67139-5
Fliedner SM, Lehnert H, Pacak K (2010) Metastatic paraganglioma. Semin Oncol 37(6):627–637. doi:10.1053/j.seminoncol.2010.10.017
Baysal BE (2002) Hereditary paraganglioma targets diverse paraganglia. J Med Genet 39(9):617–622. doi:10.1136/jmg.39.9.617
Fishbein L, Nathanson KL (2012) Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 205(1–2):1–11. doi:10.1016/j.cancergen.2012.01.009
Boedeker CC, Ridder GJ, Schipper J (2005) Paragangliomas of the head and neck: diagnosis and treatment. Fam Cancer 4(1):55–59. doi:10.1007/s10689-004-2154-z
Lee JH, Barich F, Karnell LH et al (2002) National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer 94(3):730–737. doi:10.1002/cncr.10252
DeLellis R, Lloyd R, Heitz P (2004) World Health Organization classification of tumours. IARC Press, Lyon
Salmenkivi K, Heikkila P, Haglund C, Arola J (2004) Malignancy in pheochromocytomas. Apmis 112(9):551–559. doi:10.1111/j.1600-0463.2004.apm1120901.x
Jafri M, Whitworth J, Rattenberry E et al (2013) Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol (Oxf) 78(6):898–906. doi:10.1111/cen.12074
Baysal BE, Ferrell RE, Willett-Brozick JE et al (2000) Mutations in SDHD, a mitochondrial complex II gene. Hered Paraganglioma Sci 287(5454):848–851
Astuti D, Latif F, Dallol A et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69(1):49–54. doi:10.1086/321282
Boedeker CC, Hensen EF, Neumann HP et al (2013) Genetics of hereditary head and neck paragangliomas. Head Neck. doi:10.1002/hed.23436
Hensen EF, Jordanova ES, van Minderhout IJ et al (2004) somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23(23):4076–4083. doi:10.1038/sj.onc.1207591
Kunst HP, Rutten MH, de Monnink JP et al (2011) SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer 17(2):247–254. doi:10.1158/1078-0432.CCR-10-0420
Myssiorek D, Ferlito A, Silver CE, Rodrigo JP, Baysal BE, Fagan JJ, Suarez C, Rinaldo A (2008) Screening for familial paragangliomas. Oral Oncol 44(6):532–537. doi:10.1016/j.oraloncology.2007.06.010
Offergeld C, Brase C, Yaremchuk S et al (2012) Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao.Paulo) 67((Suppl 1)):19–28
Kollert M, Minovi AA, Draf W, Bockmuhl U (2006) Cervical paragangliomas-tumor control and long-term functional results after surgery. Skull Base 16(4):185–191. doi:10.1055/s-2006-950386
Chino JP, Sampson JH, Tucci DL, Brizel DM, Kirkpatrick JP (2009) Paraganglioma of the head and neck: long-term local control with radiotherapy. Am J Clin Oncol 32(3):304–307. doi:10.1097/COC.0b013e318187dd94
King KS, Chen CC, Alexopoulos DK et al (2011) Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-d-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab 96(9):2779–2785. doi:10.1210/jc.2011-0333
Shamblin WR, ReMine WH, Sheps SG, Harrison EG Jr (1971) Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg 122(6):732–739
Kunzel J, Iro H, Hornung J, Koch M, Brase C, Klautke G, Zenk J (2012) Function-preserving therapy for jugulotympanic paragangliomas: a retrospective analysis from 2000 to 2010. Laryngoscope 122(7):1545–1551. doi:10.1002/lary.23268
Suarez C, Rodrigo JP, Boedeker CC et al (2013) Jugular and vagal paragangliomas: systematic study of management with surgery and radiotherapy. Head Neck 35(8):1195–1204. doi:10.1002/hed.22976
Suarez C, Rodrigo JP, Mendenhall WM et al (2014) Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy. Eur Arch Otorhinolaryngol 271(1):23–34. doi:10.1007/s00405-013-2384-5
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) (2007) Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.3/132013
Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346
Stoeckli SJ, Schuknecht B, Alkadhi H, Fisch U (2002) Evaluation of paragangliomas presenting as a cervical mass on color-coded Doppler sonography. Laryngoscope 112(1):143–146. doi:10.1097/00005537-200201000-00025
Mendenhall WM, Amdur RJ, Vaysberg M, Mendenhall CM, Werning JW (2011) Head and neck paragangliomas. Head Neck 33(10):1530–1534. doi:10.1002/hed.21524
Parry DM, Li FP, Strong LC, Carney JA, Carney JA, Schottenfeld D, Reimer RR, Grufferman S (1982) Carotid body tumors in humans: genetics and epidemiology. J Natl Cancer Inst 68(4):573–578
Neskey DM, Hatoum G, Modh R, Civantos F, Telischi FF, Angeli SI, Weed D, Sargi Z (2011) Outcomes after surgical resection of head and neck paragangliomas: a review of 61 patients. Skull Base 21(3):171–176. doi:10.1055/s-0031-1275251
Lack EE, Cubilla AL, Woodruff JM (1979) Paragangliomas of the head and neck region: a pathologic study of tumors from 71 patients. Hum Pathol 10(2):191–218
Power AH, Bower TC, Kasperbauer J, Link MJ, Oderich G, Cloft H, Young WF Jr, Gloviczki P (2012) Impact of preoperative embolization on outcomes of carotid body tumor resections. J Vasc Surg 56(4):979–989. doi:10.1016/j.jvs.2012.03.037
Duffis EJ, Gandhi CD, Prestigiacomo CJ et al (2012) Head, neck, and brain tumor embolization guidelines. J Neurointerv Surg 4(4):251–255. doi:10.1136/neurintsurg-2012-010350
Li G, Chang S, Adler JR Jr, Lim M (2007) Irradiation of glomus jugulare tumors: a historical perspective. Neurosurg Focus 23(6):E13. doi:10.3171/FOC-07/12/E13
Luna-Ortiz K, Rascon-Ortiz M, Villavicencio-Valencia V, Granados-Garcia M, Herrera-Gomez A (2005) Carotid body tumors: review of a 20-year experience. Oral Oncol 41(1):56–61. doi:10.1016/j.oraloncology.2004.06.006
Kasper GC, Welling RE, Wladis AR, CaJacob DE, Grisham AD, Tomsick TA, Gluckman JL, Muck PE (2006) A multidisciplinary approach to carotid paragangliomas. Vasc Endovascular Surg 40(6):467–474. doi:10.1177/1538574406290254
De Toma G, Nicolanti V, Plocco M, Cavallaro G, Letizia C, Piccirillo G, Cavallaro A (2000) Baroreflex failure syndrome after bilateral excision of carotid body tumors: an underestimated problem. J Vasc Surg 31(4):806–810. doi:10.1067/mva.2000.103789
Burnichon N, Abermil N, Buffet A, Favier J, Gimenez-Roqueplo AP (2012) The genetics of paragangliomas. Eur Ann Otorhinolaryngol Head Neck Dis 129(6):315–318. doi:10.1016/j.anorl.2012.04.007
Hermsen MA, Sevilla MA, Llorente JL et al (2010) Relevance of germline mutation screening in both familial and sporadic head and neck paraganglioma for early diagnosis and clinical management. Cell Oncol 32(4):275–283
Lima J, Feijao T, Ferreira da Silva A et al (2007) High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure–function relationships and clinical–pathological correlations. J Clin Endocrinol Metab 92(12):4853–4864. doi:10.1210/jc.2007-0640
Timmers HJ, Taieb D, Pacak K (2012) Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res 44(5):367–372. doi:10.1055/s-0031-1299712
Hallett JW Jr, Nora JD, Hollier LH, Cherry KJ Jr, Pairolero PC (1988) Trends in neurovascular complications of surgical management for carotid body and cervical paragangliomas: a fifty-year experience with 153 tumors. J Vasc Surg 7(2):284–291
Schick B, Draf W, Kahle G (1998) Jugulotympanic paraganglioma: therapy concepts under development. Laryngorhinootologie 77(8):434–443. doi:10.1055/s-2007-997004
Rattenberry E, Vialard L, Yeung A et al (2013) A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98(7):E1248–E1256. doi:10.1210/jc.2013-1319
Acknowledgments
The following are acknowledged: The Helsinki University Central Hospital Research Funds: Pekka Ranta, Elina Nikanne, Tommi Torkkeli, Jouko Nieminen, Erkki Hopsu, Kristofer Nyman and Matti Hynynen.
Conflict of interest
This research was funded by The Helsinki University Central Hospital Research Funds.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Anttila, T., Häyry, V., Nicoli, T. et al. A two-decade experience of head and neck paragangliomas in a whole population-based single centre cohort. Eur Arch Otorhinolaryngol 272, 2045–2053 (2015). https://doi.org/10.1007/s00405-014-3161-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-014-3161-9